Table 1.

Demographic characteristics of the participants included in the PPS^a and baseline seropositivity rates for those excluded from the iPPS^b.

Characteristic	All participants			9–17 years cohort			18–26 years cohort			27–45 years cohort
	Placebo	Vaccine	p value	Placebo	Vaccine	p value	Placebo	Vaccine	p value	Placebo	Vaccine	p value
N =	540	524		276	268		98	95		166	161
Age (y), median	17.2	17.4	.631	13.2	13.2	.743	24.0	24.0	.521	37.0	39.0	.044*
Height (cm), median	153	153	.250	149	150	.215	155	155	.663	155	155	.180
Weight (kg), median	45.9	46.2	.155	39.3	40.0	.559	47.1	47.9	.888	52.6	55.0	.006*
Ethnic group (n)
Han	437	435	.103	220	223	.141	84	79	.372	133	133	.646
Zhuang	45	32		26	16		7	4		12	12
Yao	58	53		30	26		7	12		21	15
Other	0	4		0	3		0	0		0	1
Baseline seropositivity rates (n, %)
HPV16	8 (1.5)	20 (3.8)	.017*	1 (0.4)	3 (1.1)	.366	3 (3.1)	3 (3.2)	1.000	4 (2.4)	14 (8.7)	.013*
HPV18	14 (2.6)	20 (3.8)	.256	5 (1.8)	5 (1.9)	1.000	3 (3.1)	4 (4.2)	.718	6 (3.6)	11 (6.8)	.190
Baseline GMTs c
HPV16	20.5	21.3	.057	20.1	20.5	.224	20.7	21.7	.453	21.1	22.5	.185
HPV18	20.8	21.2	.233	20.5	20.8	.542	21.0	21.2	.842	21.0	22.0	.267

* indicates significant differences were observed between groups.

a. PPS = Per Protocol Set which includes those who received all doses of vaccine or placebo on schedule and provided paired blood samples.

b. iPPS = Immunogenicity Per Protocol Set which excludes those who were seropositive at baseline.

c. GMTs indicates geometric mean neutralization titers.